Regencell Bioscience Holdings Ltd (RGC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Regencell Bioscience Holdings Ltd stock (RGC) is currently trading at $24.43. WallStSmart rates RGC as Sell.
- RGC PE ratio analysis and historical PE chart
- RGC PS ratio (Price-to-Sales) history and trend
- RGC intrinsic value — DCF, Graham Number, EPV models
- RGC stock price prediction 2025 2026 2027 2028 2029 2030
- RGC fair value vs current price
- RGC insider transactions and insider buying
- Is RGC undervalued or overvalued?
- Regencell Bioscience Holdings Ltd financial analysis — revenue, earnings, cash flow
- RGC Piotroski F-Score and Altman Z-Score
- RGC analyst price target and Smart Rating
Regencell Bioscience Holdings
📊 No data available
Try selecting a different time range
Smart Analysis
Regencell Bioscience Holdings Ltd (RGC) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap. Concerns around return on equity and price/book. Significant fundamental concerns warrant caution or avoidance.
Regencell Bioscience Holdings Ltd (RGC) Key Strengths (1)
Large-cap company with substantial market presence
Regencell Bioscience Holdings Ltd (RGC) Areas to Watch (3)
Company is destroying shareholder value
Very expensive at 2767.3x book value
Very low institutional interest at 0.11%
Regencell Bioscience Holdings Ltd (RGC) Detailed Analysis Report
Overall Assessment
This company scores 11/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 9.0/10) while 3 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Market Cap.
The Bear Case
The primary concerns are Return on Equity, Price/Book, Institutional Own.. Some valuation metrics including Price/Book (2767.35) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -54.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -54.80% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RGC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RGC's Price-to-Sales ratio of 4.10x trades 102% above its historical average of 2.03x (80th percentile), historically expensive. The current valuation is 25% below its historical high of 5.49x set in Feb 2022, and 20404% above its historical low of 0.02x in Jan 2025. Over the past 12 months, the PS ratio has expanded from ~0.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Regencell Bioscience Holdings Ltd (RGC) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Regencell Bioscience Holdings Ltd operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.11 indicates a conservative balance sheet with 2M in cash.
What to Watch Next
Volatility is elevated with a beta of 2.07, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Regencell Bioscience Holdings Ltd.
Bottom Line
Regencell Bioscience Holdings Ltd offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Regencell Bioscience Holdings Ltd(RGC)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Regal Entertainment Group, is a film exhibitor in the United States. The company is headquartered in Knoxville, Tennessee.